Çetin Taş

Prof. Dr. Çetin Taş

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
Çetin TaşÇetin Taş
Çetin Taş
JMJessica Mistilis
Jessica Mistilis
HNHiep X. Nguyen
Hiep X. Nguyen
PEPadmanabhan Eangoor
Padmanabhan Eangoor
JKJennifer S. Knaack
Jennifer S. Knaack
MPMark R. Prausnitz
Mark R. Prausnitz

1 August 2003 in Il Farmaco
Verified
Journal Article
Closed access
Çetin TaşÇetin Taş
Çetin Taş
YÖYalçin Özkan
Yalçin Özkan
ASAyhan Savaser
Ayhan Savaser
TBTamer Baykara
Tamer Baykara

1 October 2006 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Çetin TaşÇetin Taş
Çetin Taş
COC Ozkan
C Ozkan
ASA Savaser
A Savaser
YOY Ozkan
Y Ozkan
UTU Tasdemir
U Tasdemir
HAH Altunay
H Altunay

1 February 2012 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Çetin TaşÇetin Taş
Çetin Taş
SMSaffar Mansoor
Saffar Mansoor
HKHaripriya Kalluri
Haripriya Kalluri
VZVladimir G. Zarnitsyn
Vladimir G. Zarnitsyn
SCSeong-O Choi
Seong-O Choi
MPMark R. Prausnitz
Mark R. Prausnitz

1 January 2007 in Drug Delivery
Verified
Journal Article
Closed access
Çetin TaşÇetin Taş
Çetin Taş
YOYalcin Ozkan
Yalcin Ozkan
AOAlper Okyar
Alper Okyar
ASAyhan Savaser
Ayhan Savaser
Etodolac, a highly lipophilic anti-inflammatory drug, is widely used in rheumatoid arthritis usually at an oral dose of 200 mg twice daily. The commonest side effects during therapy with etodolac is generally gastrointestinal disturbances these are usually mild and reversible but in some patients are peptic ulcer and severe gastrointestinal bleeding. To eliminate these side effects and obtain high drug concentration at the application side, dermal application of etodolac seems to be an ideal route for administration. Hydrophilic gel formulations of etodolac were prepared with carboxymethylcellulose sodium. The effect of different terpenes (anethole, carvacrol, and menthol) as an enhancer on the percutaneous absorption of etodolac was also investigated. Permeation studies were carried out with unjacketed modified horizontal diffusion cells through cellulose membrane and rat skin. In vitro studies with cellulose membrane showed that all formulations presented the same drug release profile (p > 0.05). Ex vivo studies with excised rat skin revealed that etodolac was released and penetrated into rat skin quickly. Anethole, a hydrophobic terpene, enhanced the absorption of etodolac significantly (p < 0.05). This result is consistent with the fact that hydrophobic terpenes are effective on the percutaneous absorption of lipophilic drugs. Menthol and carvacrol, hydrophilic terpenes, did not enhance the absorption of etodolac. The lipophilicity of the enhancers seems an important factor in promoting penetration of etodolac through the skin. Since etodolac creates gastrointestinal disturbances, topical formulations of etodolac in gel form including 1% anethole could be an alternative.

1 August 2011 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
ZBZiya Bayrak
Ziya Bayrak
Çetin TaşÇetin Taş
Çetin Taş
UTUmut Tasdemir
Umut Tasdemir
HEHalil Erol
Halil Erol
COCansel Kose Ozkan
Cansel Kose Ozkan
YOYalcin Ozkan
Yalcin Ozkan